OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1061 / 1061
页数：1
相关论文
共 50 条
  • [41] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
    Remon, Jordi
    Hendriks, Lizza E. L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
  • [42] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
    Tan, Daniel Shao-Weng
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen
    Chia, Puey Ling
    De Marinis, Filippo
    Le, Xiuning
    Karachaliou, Niki
    Brutlach, Sabine
    Adrian, Svenja
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
    Jassem, Jacek
    LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 808 - 810
  • [44] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
  • [45] Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
    Choudhury, Noura J.
    Marra, Antonio
    Sui, Jane S. Y.
    Flynn, Jessica
    Yang, Soo-Ryum
    Falcon, Christina J.
    Selenica, Pier
    Schoenfeld, Adam J.
    Rekhtman, Natasha
    Gomez, Daniel
    Berger, Michael F.
    Ladanyi, Marc
    Arcila, Maria
    Rudin, Charles M.
    Riely, Gregory J.
    Kris, Mark G.
    Heller, Glenn
    Reis-Filho, Jorge S.
    Yu, Helena A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : 463 - 475
  • [46] Optimal first-line therapy for NSCLC with EGFR mutations
    Joel W. Neal
    Lecia V. Sequist
    Nature Reviews Clinical Oncology, 2010, 7 : 71 - 72
  • [47] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
  • [48] Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG 51403
    Goldberg, Sarah
    Moon, James
    Lilenbaum, Rogerio
    Politi, Katerina
    Melnick, Mary Ann
    Stinchcombe, Thomas
    Horn, Leora
    Chen, Everett
    Miao, Jieling
    Redman, Mary
    Kelly, Karen
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1220 - S1221
  • [49] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
    Chen, Y-M.
    Lin, M-C.
    Lai, C-H.
    Fang, W-F.
    Chang, H-C.
    Wang, C-C.
    Tseng, C-C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
  • [50] Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
    Zhu, Viola Weijia
    Bestvina, Christine M.
    Lopes, Gilberto
    Hamm, John Turner
    Johnson, Melissa Lynne
    Lammers, Philip Edward
    Le, Xiuning
    Marathe, Omkar
    Raez, Luis E.
    Rao, Suman
    Sabari, Joshua K.
    Scheff, Ronald J.
    Tapan, Umit
    Thompson, Jonathan Robert
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Brutlach, Sabine
    Smit, Egbert F.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345